- Medicine Name: Wegovy
- API: Semaglutide
- Dosage Form & Strength: Injection: pre-filled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg
- Manufactured By: Novo Nordisk
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:
adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).
Limitations of Use: Wegovy should not be used along with other semaglutide-containing products or any other GLP-1 receptor agonist. The efficacy and safety of coadministration with certain other products for weight loss have not been established. This medicinal product has not been studied in individuals with a history of pancreatitis.
Recommended Dosage: Wegovy is available in 5 different dose strengths, ranging from 0.25 mg to 2.4 mg. Each dose is supplied in a different color pen. It is administered once weekly. It’s administered on the same day each week, any time of day, with or without food.
Recommended Dosage in Adults: Initiate therapy with a dosage of 0.25 mg injected subcutaneously (SC) once-weekly. Then follow the dose escalation to minimize gastrointestinal side effects. In case patients do not tolerate a dose of Wegovy during dosage escalation, delay the dosage escalation for four weeks. The 0.25 mg, 0.5 mg, and 1 mg once weekly dosages are initiation and escalation dosages and are not authorized as maintenance dosages for chronic weight management. The maintenance dosage in adults is either 2.4 mg (recommended) or 1.7 mg once weekly. Consider therapy response and tolerability when selecting the maintenance dosage.
Recommended Dosage in Pediatric Patients Aged 12 Years and Older: Initiate therapy with a dosage of 0.25 mg injected subcutaneously (SC) once weekly. Then follow the Wegovy dose escalation to minimize gastrointestinal side effects. The maintenance dosage in pediatric patients aged 12 years and older is 2.4 mg once weekly.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.